Cargando…
Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
INTRODUCTION: Although the prognostic value of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPAs) in patients with rheumatoid arthritis (RA) is well established, their association with RA disease activity remains unclear. Here, we investigate this association in a large...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549866/ https://www.ncbi.nlm.nih.gov/pubmed/26307354 http://dx.doi.org/10.1186/s13075-015-0736-9 |
_version_ | 1782387367412236288 |
---|---|
author | Aletaha, Daniel Alasti, Farideh Smolen, Josef S. |
author_facet | Aletaha, Daniel Alasti, Farideh Smolen, Josef S. |
author_sort | Aletaha, Daniel |
collection | PubMed |
description | INTRODUCTION: Although the prognostic value of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPAs) in patients with rheumatoid arthritis (RA) is well established, their association with RA disease activity remains unclear. Here, we investigate this association in a large study using data from clinical trials. METHODS: We used baseline data from four recent randomized controlled clinical trials of RA. We investigated individual and composite measures of disease activity. The relationship of RF and ACPAs with these measures was investigated by using stratified analysis (comparing four groups of patients according to the presence or absence of RF and ACPAs) and matched analysis (disease activity levels compared between patients negative and patients highly positive for one autoantibody who were matched for levels of the other autoantibody as well as for age, gender, and duration of RA). RESULTS: A total of 2118 patients were analysed in the different cohorts. In the stratified analysis, RF(+) patients, regardless of ACPA status, had the highest levels of disease activity, whereas ACPA(+) patients had disease activity that was similar to or lower than that of ACPA(−) patients, both in the presence and in the absence of RF. When matched for ACPA levels, patients with highly positive RF had significantly higher disease activity for all composite indices compared with patients who were RF(−) (P = 0.0067), whereas ACPA-highly-positive and ACPA-negative patients matched for RF levels had similar disease activity, again even with the tendency toward lower disease activity for ACPA(+) patients (P = 0.054). CONCLUSION: The data presented suggest that the presence of RF has a clear association with higher levels of disease activity but that the presence of ACPAs has not and even appears to be associated with lower disease activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0736-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4549866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45498662015-08-27 Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials Aletaha, Daniel Alasti, Farideh Smolen, Josef S. Arthritis Res Ther Research Article INTRODUCTION: Although the prognostic value of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPAs) in patients with rheumatoid arthritis (RA) is well established, their association with RA disease activity remains unclear. Here, we investigate this association in a large study using data from clinical trials. METHODS: We used baseline data from four recent randomized controlled clinical trials of RA. We investigated individual and composite measures of disease activity. The relationship of RF and ACPAs with these measures was investigated by using stratified analysis (comparing four groups of patients according to the presence or absence of RF and ACPAs) and matched analysis (disease activity levels compared between patients negative and patients highly positive for one autoantibody who were matched for levels of the other autoantibody as well as for age, gender, and duration of RA). RESULTS: A total of 2118 patients were analysed in the different cohorts. In the stratified analysis, RF(+) patients, regardless of ACPA status, had the highest levels of disease activity, whereas ACPA(+) patients had disease activity that was similar to or lower than that of ACPA(−) patients, both in the presence and in the absence of RF. When matched for ACPA levels, patients with highly positive RF had significantly higher disease activity for all composite indices compared with patients who were RF(−) (P = 0.0067), whereas ACPA-highly-positive and ACPA-negative patients matched for RF levels had similar disease activity, again even with the tendency toward lower disease activity for ACPA(+) patients (P = 0.054). CONCLUSION: The data presented suggest that the presence of RF has a clear association with higher levels of disease activity but that the presence of ACPAs has not and even appears to be associated with lower disease activity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0736-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-08-26 2015 /pmc/articles/PMC4549866/ /pubmed/26307354 http://dx.doi.org/10.1186/s13075-015-0736-9 Text en © Aletaha et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Aletaha, Daniel Alasti, Farideh Smolen, Josef S. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
title | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
title_full | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
title_fullStr | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
title_full_unstemmed | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
title_short | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
title_sort | rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549866/ https://www.ncbi.nlm.nih.gov/pubmed/26307354 http://dx.doi.org/10.1186/s13075-015-0736-9 |
work_keys_str_mv | AT aletahadaniel rheumatoidfactornotantibodiesagainstcitrullinatedproteinsisassociatedwithbaselinediseaseactivityinrheumatoidarthritisclinicaltrials AT alastifarideh rheumatoidfactornotantibodiesagainstcitrullinatedproteinsisassociatedwithbaselinediseaseactivityinrheumatoidarthritisclinicaltrials AT smolenjosefs rheumatoidfactornotantibodiesagainstcitrullinatedproteinsisassociatedwithbaselinediseaseactivityinrheumatoidarthritisclinicaltrials |